Medical School · Year 3 · Obgyn · includes a quiz and discussion video

Seminar 13: Infertility

OB/GYN Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Define infertility and fecundability and apply age-based timelines for initiating evaluation
2. Perform a systematic initial evaluation of the infertile couple including female and male history and physical examination
3. Assess ovulatory function using clinical and laboratory methods and interpret ovarian reserve testing
4. Evaluate tubal patency and uterine cavity integrity using hysterosalpingography and adjunctive imaging modalities
5. Interpret semen analysis parameters and identify common causes of male factor infertility
6. Explain treatment options ranging from ovulation induction through intrauterine insemination to in vitro fertilization and address complications of assisted reproductive technology

Seminar Outline

Section 1: Definitions and Epidemiology

Infertility is clinically defined as the failure to achieve a clinical pregnancy after 12 months of regular, unprotected intercourse, a definition that reflects the expected time to conception for couples with normal fertility. Primary infertility refers to couples who have never achieved a pregnancy, while secondary infertility describes couples who have previously conceived but are now unable to do so. Fecundability, the probability of achieving a pregnancy in a single menstrual cycle, is approximately 20 to 25 percent for reproductively normal couples, while fecundity refers to the probability of achieving a live birth within a single cycle. These definitions are foundational to clinical practice and ensure that evaluation and treatment are initiated at appropriate intervals.

The timeline for initiating an infertility evaluation is stratified by female age, reflecting the profound impact of age on reproductive potential. Women under 35 years of age are evaluated after 12 months of unsuccessful conception, while women aged 35 to 40 should be evaluated after 6 months. Women over 40 years of age or those with known risk factors such as amenorrhea, known tubal disease, or a partner with known male factor warrant immediate evaluation. This age-stratified approach recognizes that reproductive capacity declines with age and that delayed evaluation may compromise treatment outcomes, particularly when time-sensitive interventions such as in vitro fertilization may be needed.

Infertility affects approximately 10 to 15 percent of couples of reproductive age, making it one of the most common reasons for gynecologic consultation. Female factor accounts for approximately 35 percent of infertility cases, while male factor is equally responsible for approximately 35 percent. Combined male and female factors are identified in approximately 20 percent of couples, and unexplained infertility, in which standard evaluation fails to identify a cause, accounts for the remaining 10 percent. This distribution underscores the importance of evaluating both partners simultaneously, as male factor is as prevalent as female factor and should not be overlooked in the initial workup.

Female age is the single most important determinant of fertility and assisted reproductive technology success. Monthly fecundability rates are 20 to 25 percent for women aged 20 to 24, declining to 15 to 20 percent by age 25 to 30, approximately 10 percent by age 35 to 39, and less than 5 percent after age 40. This decline reflects the progressive loss of oocyte quantity and quality, with increasing rates of aneuploidy contributing to both reduced conception rates and higher miscarriage rates. The age-related decline in fertility is not fully overcome by assisted reproductive technology, and female age remains the strongest predictor of in vitro fertilization success. Counseling patients about the impact of age on fertility is an essential component of reproductive health education.

<image>Panel A: Infertility definitions showing primary (never conceived), secondary (prior pregnancy, now unable), fecundability (20 to 25 percent per cycle), and fecundity (probability of live birth per cycle) with clinical pregnancy timeline of 12 months. Panel B: Age-stratified evaluation timeline showing under 35 (evaluate at 12 months), 35 to 40 (evaluate at 6 months), over 40 (immediate evaluation), and known risk factors (immediate evaluation). Panel C: Infertility etiology pie chart showing female factor (35 percent), male factor (35 percent), combined factors (20 percent), and unexplained (10 percent). Panel D: Age versus fecundability curve showing monthly conception rates declining from 20 to 25 percent at ages 20 to 24 through 10 percent at 35 to 39 to less than 5 percent after 40 with corresponding oocyte quality annotations.</image>

Section 2: Initial Evaluation

The female history in the infertility evaluation focuses on factors that affect ovulation, tubal function, uterine receptivity, and overall reproductive health. Menstrual history is particularly important, as regular cycles of 24 to 38 days strongly suggest ovulatory function. A gynecologic history of sexually transmitted infections, pelvic inflammatory disease, or prior pelvic surgery raises concern for tubal factor. Sexual history should address the frequency and timing of intercourse relative to the fertile window, as well as any dysfunction. Medical history including thyroid disease, diabetes, and autoimmune conditions may contribute to subfertility, and a surgical history of pelvic procedures increases the risk of adhesive disease.

The male history is equally important and addresses reproductive, medical, and environmental factors that may impair spermatogenesis or sperm delivery. Sexual history should document intercourse frequency, erectile or ejaculatory dysfunction, and lubricant use, as some lubricants are spermicidal. Medical history of varicocele, cryptorchidism, prior genitourinary infections, or sexually transmitted infections may affect fertility. Surgical history, particularly hernia repair or vasectomy, may compromise the reproductive tract. Environmental and occupational exposures to heat, radiation, heavy metals, or toxins can impair spermatogenesis, and medications including exogenous testosterone (which suppresses endogenous spermatogenesis), anabolic steroids, and chemotherapy must be specifically reviewed.

The female physical examination in the infertility evaluation targets signs of conditions that may impair fertility. Body mass index at either extreme, both underweight and obese, is associated with ovulatory dysfunction and reduced conception rates. Thyroid examination may reveal nodules or enlargement suggesting thyroid disease. Breast examination includes assessment for galactorrhea, which may indicate hyperprolactinemia. Pelvic examination evaluates for masses, tenderness, or anatomic abnormalities, and signs of hyperandrogenism including hirsutism, acne, and acanthosis nigricans may suggest polycystic ovary syndrome or insulin resistance.

The male physical examination is ideally performed by a urologist and provides important diagnostic information that complements the semen analysis. Testicular volume is assessed using an orchidometer, with volumes less than 4 milliliters considered small and suggesting impaired spermatogenesis. Varicocele, described as a "bag of worms" feel in the pampiniform plexus above the testicle, is the most common correctable cause of male infertility and is best detected with the patient standing and performing a Valsalva maneuver. Congenital bilateral absence of the vas deferens is associated with cystic fibrosis transmembrane conductance regulator gene mutations and presents as palpable absence of the vas on scrotal examination. Assessment of secondary sexual characteristics including body habitus, voice, and hair distribution screens for hypogonadism that may impair testosterone production and spermatogenesis.

<image>Panel A: Female infertility history checklist showing menstrual regularity assessment, gynecologic history (STI, PID, surgery), sexual history (frequency, timing, dysfunction), medical conditions (thyroid, diabetes, autoimmune), and surgical history with pelvic adhesion risk. Panel B: Male infertility history checklist showing sexual history (frequency, dysfunction, lubricant use), medical history (varicocele, cryptorchidism), surgical history (hernia repair, vasectomy), environmental exposures (heat, toxins), and medication review (testosterone, chemotherapy). Panel C: Female physical examination findings showing BMI extremes, thyroid assessment, breast examination for galactorrhea, pelvic examination for masses and tenderness, and hyperandrogenism signs (hirsutism, acne, acanthosis nigricans). Panel D: Male physical examination showing orchidometer testicular volume measurement, varicocele detection with Valsalva, vas deferens palpation for congenital absence, and secondary sexual characteristic assessment for hypogonadism.</image>

Section 3: Ovulatory Assessment

Confirming ovulation is a critical early step in the female infertility evaluation, as ovulatory dysfunction is one of the most common and treatable causes of infertility. Regular menstrual cycles occurring every 24 to 38 days are the strongest clinical indicator of ovulatory function, though not all regular cycles are ovulatory. A mid-luteal serum progesterone level, typically obtained on cycle day 21 in a 28-day cycle, exceeding 3 nanograms per milliliter confirms that ovulation has occurred. Urinary luteinizing hormone surge detection kits predict ovulation 24 to 36 hours before it occurs and are useful for timing intercourse. Basal body temperature charting documents a post-ovulatory rise of approximately 0.4 degrees Fahrenheit but is retrospective and has largely been supplanted by more practical methods. Serial transvaginal ultrasound provides the most definitive confirmation of follicular development, dominant follicle collapse, and corpus luteum formation.

Ovulatory dysfunction encompasses a spectrum of conditions that disrupt the normal hypothalamic-pituitary-ovarian axis. Polycystic ovary syndrome is the most common cause of anovulatory infertility, affecting approximately 70 percent of women with oligo-ovulation or anovulation. Hypothalamic amenorrhea results from energy deficit due to stress, excessive exercise, or low body weight, which suppresses gonadotropin-releasing hormone pulsatility. Hyperprolactinemia, whether from a pituitary prolactinoma or dopamine-blocking medications, inhibits gonadotropin secretion and prevents ovulation. Thyroid dysfunction, both hypothyroidism and hyperthyroidism, can disrupt ovulatory function and should be corrected before initiating ovulation induction. Premature ovarian insufficiency, characterized by elevated follicle-stimulating hormone levels before age 40, represents a depleted oocyte pool with very limited treatment options.

Laboratory testing in the ovulatory assessment includes both confirmation of ovulation and assessment of ovarian reserve. Day 3 follicle-stimulating hormone, obtained on cycle days 2 to 4, provides a measure of ovarian reserve, with values exceeding 10 to 15 international units per liter suggesting diminished reserve. Day 3 estradiol is measured concurrently, as an elevated level may falsely suppress follicle-stimulating hormone and mask diminished reserve. Anti-Mullerian hormone can be measured on any day of the cycle and provides a direct marker of the remaining follicular pool, with values below 1 nanogram per milliliter suggesting diminished ovarian reserve. Thyroid-stimulating hormone screens for thyroid dysfunction, and prolactin screens for hyperprolactinemia, both of which are treatable causes of ovulatory dysfunction.

Ovarian reserve testing predicts the expected response to ovarian stimulation but does not represent an absolute prediction of the ability to conceive. An elevated day 3 follicle-stimulating hormone exceeding 10 to 15 international units per liter suggests a reduced follicular pool and typically predicts a poor response to gonadotropin stimulation. Anti-Mullerian hormone below 1 nanogram per milliliter similarly indicates diminished reserve, while very low levels below 0.3 nanogram per milliliter suggest very limited remaining oocytes. The antral follicle count, determined by transvaginal ultrasound in the early follicular phase, provides a visual assessment of the recruitable follicle pool, with fewer than 5 to 7 antral follicles across both ovaries considered concerning. It is important to counsel patients that while these markers predict treatment response, women with diminished ovarian reserve may still conceive spontaneously, and normal reserve testing does not guarantee fertility.

<image>Panel A: Ovulation confirmation methods showing regular menstrual history, mid-luteal progesterone (greater than 3 ng/mL), LH surge detection kits (24 to 36 hours before ovulation), basal body temperature charting (0.4 degree rise), and serial ultrasound (follicle development and collapse). Panel B: Ovulatory dysfunction causes showing PCOS (most common, 70 percent of anovulation), hypothalamic amenorrhea (stress, exercise, weight), hyperprolactinemia (prolactinoma, medications), thyroid dysfunction, and premature ovarian insufficiency. Panel C: Laboratory testing panel showing day 3 FSH and estradiol (ovarian reserve), AMH (any day, follicular pool marker), TSH (thyroid function), and prolactin (hyperprolactinemia screening). Panel D: Ovarian reserve interpretation showing FSH greater than 10 to 15 (diminished reserve), AMH less than 1 (concerning) and less than 0.3 (very limited), AFC less than 5 to 7 (reduced pool), and counseling note that reserve predicts treatment response not absolute fertility.</image>

Section 4: Tubal and Uterine Evaluation

The hysterosalpingogram is a fluoroscopic radiographic study that serves as the standard first-line evaluation of tubal patency and uterine cavity morphology. The procedure is performed during the follicular phase after menstrual cessation but before ovulation to avoid disrupting a potential early pregnancy. Radiopaque contrast is injected through the cervix under fluoroscopic guidance, filling the uterine cavity and flowing through the fallopian tubes when they are patent, with spillage of contrast into the peritoneal cavity confirming bilateral tubal patency. The study also evaluates the uterine cavity for filling defects that may indicate polyps, fibroids, or adhesions. An additional therapeutic benefit has been documented, as the tubal flushing effect of contrast may transiently improve fertility rates, particularly when oil-based contrast is used.

Tubal factor infertility accounts for approximately 25 to 35 percent of female infertility and most commonly results from damage caused by pelvic inflammatory disease. Chlamydia trachomatis is the leading cause of tubal disease, often producing subclinical infection that damages the tubal epithelium without obvious clinical symptoms. Prior ectopic pregnancy is associated with ipsilateral tubal damage and increased risk of recurrent ectopic pregnancy. Endometriosis can cause tubal distortion through adhesion formation and direct implant involvement. Hydrosalpinx, the accumulation of fluid in a distally obstructed fallopian tube, is associated with particularly poor fertility outcomes, and current evidence supports salpingectomy of hydrosalpinges before in vitro fertilization to improve implantation rates by eliminating the toxic fluid that may drain into the uterine cavity.

Uterine factors that may impair fertility include structural abnormalities that distort the endometrial cavity or impair implantation. Submucosal leiomyomas that protrude into the uterine cavity are associated with reduced implantation and increased miscarriage rates, and hysteroscopic myomectomy improves fertility outcomes. Endometrial polyps may interfere with implantation and should be removed in the setting of infertility. Intrauterine adhesions, known as Asherman syndrome, result from aggressive curettage or endometrial infection and produce partial or complete obliteration of the uterine cavity. Uterine septum, the most common congenital uterine anomaly, is associated with increased miscarriage risk and may benefit from hysteroscopic resection, though the evidence for improved live birth rates after septoplasty remains debated.

Additional imaging modalities complement the hysterosalpingogram when further characterization of tubal or uterine pathology is needed. Saline infusion sonography involves instillation of sterile saline into the uterine cavity during transvaginal ultrasound, providing excellent visualization of intracavitary lesions such as polyps and submucosal fibroids. Hysteroscopy offers direct visualization of the uterine cavity and allows concurrent therapeutic intervention including polypectomy, myomectomy, and adhesiolysis. Diagnostic laparoscopy provides assessment of the pelvic anatomy including the tubal serosa, endometriosis implants, and adhesions, and remains the gold standard for diagnosing peritoneal endometriosis. Pelvic MRI offers detailed characterization of uterine anomalies, adenomyosis, and complex myometrial pathology without the invasiveness of surgery.

<image>Panel A: Hysterosalpingogram procedure showing fluoroscopic setup, transcervical contrast injection, uterine cavity opacification, bilateral tubal fill with peritoneal spillage confirming patency, and common findings (normal, unilateral blockage, hydrosalpinx). Panel B: Tubal factor causes showing PID and chlamydia (leading cause), prior ectopic pregnancy, endometriosis with adhesions, and hydrosalpinx with recommendation for salpingectomy before IVF. Panel C: Uterine factors affecting fertility showing submucosal fibroids (reduced implantation), endometrial polyps (impaired implantation), Asherman syndrome (adhesions from curettage), and uterine septum (increased miscarriage). Panel D: Additional imaging modalities showing saline infusion sonography (intracavitary lesions), hysteroscopy (direct visualization and treatment), laparoscopy (endometriosis and adhesions), and MRI (anomalies and adenomyosis).</image>

Section 5: Male Factor Evaluation

The semen analysis is the cornerstone of male factor evaluation and should be one of the first tests ordered in any infertility workup. The World Health Organization reference values define the lower limits of normal: ejaculate volume of at least 1.5 milliliters, sperm concentration of at least 15 million per milliliter, total sperm count of at least 39 million, total motility of at least 40 percent with at least 32 percent progressive motility, and normal morphology of at least 4 percent by strict Kruger criteria. The specimen should be collected after 2 to 5 days of abstinence and analyzed within one hour of collection. A single abnormal result should be confirmed with a repeat analysis performed at least 2 to 4 weeks later, as spermatogenesis takes approximately 74 days and individual samples can vary significantly.

Abnormal semen analysis results are categorized using standardized terminology that describes the specific parameter affected. Oligospermia refers to a reduced sperm concentration, while asthenospermia describes diminished motility. Teratospermia indicates abnormal morphology exceeding the reference range, and the combination of all three abnormalities is termed oligo-astheno-teratospermia, which is the most common pattern of severe male factor infertility. Azoospermia, the complete absence of sperm in the ejaculate, requires differentiation between obstructive causes in which spermatogenesis is normal but the ductal system is blocked, and non-obstructive causes in which spermatogenesis itself is impaired. This distinction has critical implications for treatment, as surgical sperm retrieval may be possible in obstructive azoospermia.

The causes of male factor infertility span anatomic, genetic, hormonal, and environmental categories. Varicocele is the most common correctable cause, present in approximately 15 percent of the general male population and up to 40 percent of infertile men, and causes impaired spermatogenesis through elevated scrotal temperature and oxidative stress. Idiopathic male infertility accounts for 30 to 40 percent of cases in which no identifiable cause is found. Genetic causes include Y-chromosome microdeletions, which affect specific regions critical for spermatogenesis, and Klinefelter syndrome with a 47,XXY karyotype. Obstructive causes include prior vasectomy, congenital bilateral absence of the vas deferens, and post-infectious scarring. Exogenous testosterone supplementation is an increasingly recognized iatrogenic cause that suppresses the hypothalamic-pituitary-gonadal axis and inhibits spermatogenesis, and its discontinuation is essential before fertility can be expected to recover.

Further evaluation of an abnormal semen analysis follows a structured approach guided by the specific abnormality identified. A repeat analysis confirms persistent abnormalities and excludes transient causes such as febrile illness, medication use, or collection errors. Hormonal evaluation including follicle-stimulating hormone, testosterone, and luteinizing hormone distinguishes between primary testicular failure (elevated follicle-stimulating hormone, low testosterone) and secondary hypogonadism (low gonadotropins). Genetic testing with karyotype analysis and Y-chromosome microdeletion studies is indicated for men with severe oligospermia or azoospermia, as findings may affect treatment options and have implications for offspring. Cystic fibrosis transmembrane conductance regulator gene testing is essential when congenital bilateral absence of the vas deferens is identified. Urology referral is recommended for severe male factor, azoospermia, varicocele assessment, or when surgical sperm retrieval may be needed for assisted reproduction.

<image>Panel A: Semen analysis reference values showing WHO criteria for volume (at least 1.5 mL), concentration (at least 15 million per mL), total count (at least 39 million), motility (at least 40 percent total, 32 percent progressive), and morphology (at least 4 percent normal forms) with collection protocol. Panel B: Abnormal semen terminology showing oligospermia (low count), asthenospermia (low motility), teratospermia (abnormal morphology), OAT (combined), and azoospermia (absent sperm) with obstructive versus non-obstructive distinction. Panel C: Male factor causes showing varicocele (most common correctable, 40 percent of infertile men), idiopathic (30 to 40 percent), genetic (Y-deletion, Klinefelter), obstructive (vasectomy, CBAVD), and exogenous testosterone (iatrogenic suppression). Panel D: Further evaluation pathway showing repeat analysis, hormonal panel (FSH, testosterone, LH), genetic testing (karyotype, Y-deletion), CFTR testing for CBAVD, and urology referral criteria.</image>

Section 6: Treatment -- Ovulation Induction

Lifestyle modifications form the foundation of fertility treatment and should be addressed before or concurrent with pharmacologic intervention. Weight normalization is particularly important, as both underweight and obese body mass indices are associated with ovulatory dysfunction and reduced conception rates. Weight loss of as little as 5 to 10 percent in overweight or obese women can restore ovulatory cycles and improve spontaneous conception rates. Smoking cessation is essential, as tobacco use accelerates ovarian aging, reduces oocyte quality, and diminishes in vitro fertilization success rates. Alcohol consumption should be limited, and patients should be counseled that intercourse every 1 to 2 days around the time of ovulation maximizes the chance of conception without requiring precise timing of the fertile window.

Clomiphene citrate is a selective estrogen receptor modulator that has been a mainstay of ovulation induction for decades. It functions by blocking estrogen receptors at the hypothalamus, thereby releasing the hypothalamic-pituitary axis from negative feedback and increasing follicle-stimulating hormone and luteinizing hormone secretion. The standard starting dose is 50 milligrams daily for 5 days, beginning on cycle day 3 or day 5, with dose escalation to a maximum of 150 milligrams if ovulation is not achieved. Monitoring can be performed with ovulation predictor kits for low-complexity management or with transvaginal ultrasound for closer follicular assessment. Approximately 80 percent of anovulatory women will ovulate with clomiphene, and 30 to 40 percent will conceive within six cycles. Side effects include hot flashes, visual disturbances, mood changes, and a multiple pregnancy rate of approximately 8 to 10 percent.

Letrozole, an aromatase inhibitor, has emerged as the preferred first-line agent for ovulation induction in women with polycystic ovary syndrome. Its mechanism involves inhibiting the enzyme aromatase, which converts androgens to estrogens, thereby lowering peripheral estrogen levels and releasing the hypothalamic-pituitary axis from negative feedback to increase endogenous gonadotropin secretion. The standard dose is 2.5 to 7.5 milligrams daily for 5 days beginning on cycle day 3. The landmark PPCOS II trial demonstrated superior ovulation and live birth rates with letrozole compared to clomiphene in women with polycystic ovary syndrome. Letrozole produces a lower multiple pregnancy rate than clomiphene, as it more consistently generates a single dominant follicle, and it does not have the anti-estrogenic cervical mucus and endometrial effects that may limit clomiphene effectiveness.

Gonadotropin therapy provides exogenous follicle-stimulating hormone, with or without luteinizing hormone activity, to directly stimulate ovarian follicular development. Injectable gonadotropins are indicated when oral ovulation induction agents fail or when controlled ovarian stimulation is needed for intrauterine insemination or in vitro fertilization. Monitoring with serial transvaginal ultrasound and serum estradiol is mandatory to assess follicular response and minimize the risk of complications. The primary risks of gonadotropin therapy are multiple pregnancy, which may be as high as 20 to 30 percent with ovulation induction protocols, and ovarian hyperstimulation syndrome, a potentially life-threatening condition characterized by massive ovarian enlargement and third-space fluid shifts. Strict monitoring criteria for cycle cancellation when an excessive number of mature follicles develop are essential to minimize these risks.

<image>Panel A: Lifestyle modification targets showing weight normalization (5 to 10 percent loss restores ovulation), smoking cessation (accelerates ovarian aging), alcohol limitation, and intercourse timing (every 1 to 2 days around ovulation). Panel B: Clomiphene citrate mechanism and protocol showing hypothalamic estrogen receptor blockade, 50 to 150 mg dosing on days 3 to 7 or 5 to 9, 80 percent ovulation rate, 30 to 40 percent conception rate, and 8 to 10 percent multiple pregnancy rate. Panel C: Letrozole mechanism and superiority showing aromatase inhibition, 2.5 to 7.5 mg dosing on days 3 to 7, PPCOS II trial results (superior live birth versus clomiphene), lower multiple rate, and no anti-estrogenic endometrial effects. Panel D: Gonadotropin therapy showing injectable FSH administration, mandatory ultrasound and estradiol monitoring, indications (failed oral agents, IUI, IVF), and risks (20 to 30 percent multiples, OHSS) with cancellation criteria.</image>

Section 7: Treatment -- Procedures

Intrauterine insemination is a procedure in which processed, concentrated sperm are placed directly into the uterine cavity at the time of ovulation to increase the number of motile sperm reaching the fallopian tubes. The semen sample is collected and processed through washing and concentration techniques that remove seminal plasma, debris, and non-motile sperm. Timing is coordinated with ovulation, typically 24 to 36 hours after a detected luteinizing hormone surge or human chorionic gonadotropin trigger injection. Intrauterine insemination is indicated for mild male factor infertility, unexplained infertility, cervical factor, and donor sperm insemination. Success rates range from 10 to 20 percent per cycle when combined with ovulation induction, and most practitioners recommend 3 to 4 cycles before escalating to in vitro fertilization.

In vitro fertilization is the most advanced and effective assisted reproductive technology, involving a multistep process of ovarian stimulation, oocyte retrieval, fertilization, and embryo transfer. Controlled ovarian stimulation with gonadotropins produces multiple mature follicles, which are aspirated under transvaginal ultrasound guidance in a minor surgical procedure. Harvested oocytes are combined with sperm in the laboratory, either through conventional insemination in which sperm and oocytes are co-incubated, or through intracytoplasmic sperm injection. Embryos are cultured to either the cleavage stage (day 3) or the blastocyst stage (day 5) before transfer to the uterus using a thin catheter under ultrasound guidance. Success rates range from approximately 30 to 50 percent per transfer cycle, with female age being the most important determinant of outcome.

Intracytoplasmic sperm injection is a micromanipulation technique in which a single spermatozoon is directly injected into the cytoplasm of a mature oocyte using a fine micropipette. This technique was developed to overcome severe male factor infertility in which sperm concentration, motility, or morphology is so compromised that conventional fertilization would be unlikely to succeed. Intracytoplasmic sperm injection is also used when sperm are surgically retrieved from the testis or epididymis, as in cases of obstructive azoospermia. Fertilization and pregnancy rates with intracytoplasmic sperm injection are comparable to conventional in vitro fertilization when oocyte quality is normal, demonstrating that the technique effectively bypasses the natural fertilization barriers. The procedure has expanded the potential for biological parenthood to men who would previously have had no option other than donor sperm.

Donor gametes provide reproductive options for individuals and couples in whom one or both partners cannot contribute viable gametes. Donor sperm is indicated for men with azoospermia that is not amenable to surgical sperm retrieval, severe untreatable male factor, genetic disease that the couple wishes to avoid transmitting, or single women and same-sex female couples desiring pregnancy. Donor oocytes are used for women with premature ovarian insufficiency, advanced reproductive age, poor oocyte quality, or genetic disease. Donor embryo transfer utilizes embryos donated by couples who have completed their families after in vitro fertilization and is an option when both male and female gametes are unavailable. All donor gamete use requires psychological counseling for all parties, informed consent regarding disclosure to offspring, and adherence to regulatory guidelines for infectious disease screening and genetic testing of donors.

<image>Panel A: Intrauterine insemination procedure showing semen collection, sperm washing and concentration, catheter insertion through cervix into uterine cavity, timing with LH surge or trigger, 10 to 20 percent per cycle success rate, and 3 to 4 cycle recommendation before IVF. Panel B: In vitro fertilization process flowchart showing controlled ovarian stimulation, transvaginal oocyte retrieval, laboratory fertilization (conventional or ICSI), embryo culture (day 3 cleavage or day 5 blastocyst), and ultrasound-guided embryo transfer with 30 to 50 percent success rate. Panel C: Intracytoplasmic sperm injection technique showing micropipette injection of single sperm into oocyte cytoplasm, indications (severe male factor, surgically retrieved sperm), and comparable outcomes to conventional IVF. Panel D: Donor gamete options showing donor sperm (azoospermia, genetic disease, single women), donor oocytes (POI, advanced age, genetic disease), and donor embryo (both gametes needed) with counseling and screening requirements.</image>

Section 8: Specific Conditions

Polycystic ovary syndrome-related infertility follows a stepwise treatment algorithm that begins with lifestyle modification. Weight loss of 5 to 10 percent of body weight in overweight or obese women can restore spontaneous ovulation and improve both natural and treatment-assisted conception rates. Letrozole is the recommended first-line pharmacologic agent for ovulation induction in polycystic ovary syndrome based on the PPCOS II trial demonstrating superior live birth rates compared to clomiphene citrate. Clomiphene citrate remains an acceptable alternative, particularly in settings where letrozole availability is limited. Second-line treatment options include gonadotropin therapy, which requires close monitoring due to the high sensitivity of polycystic ovaries to exogenous stimulation, and in vitro fertilization for women who do not conceive with ovulation induction. Metformin may be used as an adjunct to ovulation induction agents, as it improves insulin sensitivity and may enhance ovulatory response, particularly in obese women.

Endometriosis-associated infertility is managed according to the revised American Society for Reproductive Medicine staging system, which classifies disease severity from minimal to severe. Minimal to mild endometriosis may be managed expectantly in younger patients, with intrauterine insemination or in vitro fertilization offered when spontaneous conception does not occur within a reasonable timeframe. Moderate to severe endometriosis often warrants surgical treatment to excise or ablate implants, lyse adhesions, and restore normal pelvic anatomy before proceeding to in vitro fertilization. Endometriomas larger than 3 to 4 centimeters may be excised before in vitro fertilization, though the impact of cystectomy on ovarian reserve must be carefully considered. Importantly, medical suppression of endometriosis with hormonal therapy does not improve fertility and delays time to conception, as these treatments are contraceptive by nature.

Tubal factor infertility management depends on the location, extent, and nature of the tubal disease. Mild distal tubal disease or peritubal adhesions may respond to surgical repair, particularly in younger women with otherwise favorable fertility factors. Severe bilateral tubal disease, particularly when both tubes are obstructed or damaged, is best treated with in vitro fertilization, which bypasses the tubes entirely. Hydrosalpinx requires special attention because the fluid within the obstructed tube can drain into the uterine cavity and adversely affect embryo implantation; salpingectomy or proximal tubal occlusion before in vitro fertilization has been shown to significantly improve implantation and live birth rates. The decision between tubal surgery and direct progression to in vitro fertilization should consider the patient's age, ovarian reserve, the presence of additional infertility factors, and patient preference.

Unexplained infertility is diagnosed when a standard evaluation including documentation of ovulation, patent fallopian tubes, and a normal semen analysis fails to reveal a cause. This diagnosis of exclusion affects approximately 10 percent of infertile couples and likely represents subtle abnormalities in oocyte quality, fertilization, tubal function, or endometrial receptivity that are not detected by conventional testing. Treatment follows an empiric stepwise approach beginning with ovulation induction using clomiphene or letrozole combined with intrauterine insemination for 3 to 4 cycles. If unsuccessful, treatment advances to gonadotropin therapy combined with intrauterine insemination for an additional 3 to 4 cycles. In vitro fertilization is recommended when less intensive treatments fail and is the most effective treatment for unexplained infertility, with success rates that exceed those achieved with any combination of ovulation induction and intrauterine insemination.

<image>Panel A: PCOS infertility treatment ladder showing lifestyle modification and weight loss (5 to 10 percent), letrozole (first-line per PPCOS II), clomiphene (alternative), gonadotropins (second-line with close monitoring), IVF (refractory cases), and metformin (adjunct for insulin resistance). Panel B: Endometriosis and fertility management by stage showing minimal-mild (expectant or IUI or IVF), moderate-severe (surgery then IVF), endometrioma considerations (cystectomy versus ovarian reserve), and principle that medical suppression does not improve fertility. Panel C: Tubal factor management decision tree showing mild disease (surgical repair in young patients), severe bilateral disease (IVF), and hydrosalpinx (salpingectomy before IVF for improved implantation rates). Panel D: Unexplained infertility stepwise treatment showing oral ovulation induction plus IUI (3 to 4 cycles), gonadotropins plus IUI (3 to 4 cycles), and IVF (most effective treatment) with escalation criteria.</image>

Section 9: ART Complications and Outcomes

Ovarian hyperstimulation syndrome is the most serious complication of controlled ovarian stimulation and results from excessive ovarian response to gonadotropin therapy. Mild ovarian hyperstimulation syndrome presents with abdominal bloating and mild discomfort, while moderate disease produces clinically significant ascites, nausea, and ovarian enlargement to 5 to 12 centimeters. Severe ovarian hyperstimulation syndrome is characterized by tense ascites, pleural effusion, hemoconcentration with hematocrit exceeding 45 percent, and oliguria, with critical cases progressing to renal failure, thromboembolism, and acute respiratory distress syndrome. Prevention strategies include the use of a gonadotropin-releasing hormone agonist trigger instead of human chorionic gonadotropin, which produces a shorter and less intense luteal stimulation, and the "freeze-all" approach in which all embryos are cryopreserved and transfer is deferred to a subsequent unstimulated cycle.

Multiple pregnancy is a significant iatrogenic complication of fertility treatment that carries substantial maternal and neonatal risks. In vitro fertilization-related multiple pregnancy is directly related to the number of embryos transferred, and current practice strongly favors elective single embryo transfer when high-quality blastocysts are available, which has dramatically reduced twin and higher-order multiple rates without significantly compromising overall live birth rates. Gonadotropin ovulation induction carries a particularly high risk of higher-order multiple pregnancy because the number of ovulated follicles cannot be precisely controlled. The risks of multiple pregnancy include preterm delivery, low birth weight, neonatal intensive care admission, gestational diabetes, preeclampsia, and postpartum hemorrhage. Strict adherence to society guidelines for embryo transfer number is essential to minimize these avoidable complications.

The success of in vitro fertilization is influenced by multiple factors, with female age being the most important and most consistent predictor. Live birth rates per embryo transfer are approximately 40 to 50 percent for women under 35, declining to 30 to 35 percent at ages 35 to 37, 20 to 25 percent at ages 38 to 40, and less than 10 percent after age 42. The specific diagnosis influences outcomes, with tubal factor and male factor generally having better prognosis than diminished ovarian reserve or advanced age. Embryo quality, assessed by morphologic grading and developmental stage, is a strong predictor of implantation potential, and preimplantation genetic testing for aneuploidy can improve per-transfer success rates by selecting euploid embryos. Uterine receptivity, influenced by endometrial thickness, pattern, and the absence of intracavitary pathology, also affects implantation outcomes.

The psychological impact of infertility and its treatment is substantial and should be addressed as an integral component of care. Stress levels in infertile couples are comparable to those experienced by patients with chronic diseases such as cancer and HIV, and the treatment process itself adds additional psychological burden through its invasiveness, uncertainty, and financial strain. Depression and anxiety are more prevalent in infertile women and may worsen with treatment failure. Relationship strain is common as couples navigate the emotional, physical, and financial demands of treatment. Clinicians should routinely screen for psychological distress, offer referral to mental health professionals experienced in reproductive psychology, and connect patients with peer support groups that provide validation and coping strategies.

<image>Panel A: Ovarian hyperstimulation syndrome severity spectrum showing mild (bloating, discomfort), moderate (ascites, nausea, ovarian enlargement 5 to 12 cm), severe (tense ascites, pleural effusion, hemoconcentration, oliguria), and critical (renal failure, thromboembolism, ARDS) with prevention strategies (GnRH agonist trigger, freeze-all). Panel B: Multiple pregnancy risk reduction showing elective single embryo transfer policy, IVF twin rate reduction with SET, gonadotropin monitoring with cancellation criteria, and maternal-neonatal risks of multiple gestation. Panel C: IVF success rates by age showing under 35 (40 to 50 percent), 35 to 37 (30 to 35 percent), 38 to 40 (20 to 25 percent), and over 42 (less than 10 percent) with additional factors including diagnosis, embryo quality, and uterine receptivity. Panel D: Psychological impact framework showing stress comparable to chronic disease, depression and anxiety prevalence, relationship strain, and supportive care recommendations including mental health referral and peer support groups.</image>

Section 10: Special Topics

Fertility preservation has become an essential component of reproductive medicine, offering patients the opportunity to safeguard their reproductive potential before gonadotoxic treatments or as part of elective family planning. For women facing cancer treatment, oocyte or embryo cryopreservation through controlled ovarian stimulation and retrieval can be completed within approximately 2 weeks, making it feasible even when oncologic treatment is time-sensitive. Ovarian tissue cryopreservation is an alternative for prepubertal patients or those who cannot delay treatment, though it remains less established than oocyte freezing. Sperm cryopreservation is straightforward and should be offered to all men before chemotherapy, radiation, or gonadotoxic treatment. Social egg freezing for age-related fertility preservation is increasingly common, with outcomes strongly dependent on the age at freezing, with optimal results when performed before age 35. Transgender individuals should be counseled about fertility preservation options before initiating gender-affirming hormone therapy, as both estrogen and testosterone can impair gamete production.

Preimplantation genetic testing encompasses several techniques that analyze embryonic DNA before transfer to the uterus. Preimplantation genetic testing for aneuploidy screens for chromosomal number abnormalities and is the most commonly performed type, aimed at improving per-transfer pregnancy rates and reducing miscarriage by selecting euploid embryos. Preimplantation genetic testing for monogenic disorders screens for specific single-gene conditions when one or both parents are carriers, such as cystic fibrosis, sickle cell disease, or Huntington disease. Preimplantation genetic testing for structural rearrangements evaluates embryos from parents carrying balanced chromosomal translocations or inversions. All forms of preimplantation genetic testing require biopsy of trophectoderm cells at the blastocyst stage, with results available within 1 to 2 weeks during which embryos are cryopreserved awaiting transfer.

Recurrent pregnancy loss, defined as two or more consecutive clinical pregnancy losses, affects approximately 1 to 2 percent of couples and warrants systematic evaluation. The most common identified cause is parental chromosomal abnormality, typically a balanced translocation, identified by karyotype analysis of both partners. Uterine anomalies including septum, fibroids, and adhesions can be assessed by imaging and corrected surgically. Antiphospholipid syndrome is an important treatable cause diagnosed by the presence of anticardiolipin antibodies, lupus anticoagulant, or anti-beta-2 glycoprotein I antibodies on two occasions at least 12 weeks apart, and is treated with low-dose aspirin and heparin during subsequent pregnancies. Hormonal causes including thyroid dysfunction and uncontrolled diabetes should be corrected, though in approximately 50 percent of cases no cause is identified, and supportive care with close early pregnancy monitoring improves outcomes even without specific intervention.

Third-party reproduction encompasses arrangements in which a person other than the intended parent contributes gametes or gestational capacity. Gestational carrier arrangements involve transfer of the intended parents' embryo to a gestational carrier who has no genetic relationship to the resulting child, and this option is used by women with absent or non-functional uteri, severe medical contraindications to pregnancy, or same-sex male couples. Traditional surrogacy, in which the carrier contributes her own oocyte, is now rarely practiced due to the more complex legal and ethical considerations. Legal contracts are essential in all third-party reproduction arrangements and must address parental rights, financial responsibilities, and decision-making authority. Psychological counseling for all parties, including the intended parents, the carrier or donor, and potentially the resulting children, is considered standard of care.

<image>Panel A: Fertility preservation options showing oocyte and embryo cryopreservation (2-week stimulation for cancer patients), ovarian tissue cryopreservation (prepubertal or urgent cases), sperm cryopreservation (before gonadotoxic treatment), social egg freezing (optimal before 35), and transgender preservation (before hormone therapy). Panel B: Preimplantation genetic testing types showing PGT-A (aneuploidy screening for improved per-transfer rates), PGT-M (monogenic disorders such as CF, sickle cell, Huntington), and PGT-SR (structural rearrangements) with trophectoderm biopsy at blastocyst stage. Panel C: Recurrent pregnancy loss evaluation showing parental karyotype (balanced translocation), uterine evaluation (septum, fibroids, adhesions), antiphospholipid syndrome testing (anticardiolipin, lupus anticoagulant), hormonal assessment (thyroid, diabetes), and unexplained (50 percent, supportive care). Panel D: Third-party reproduction options showing gestational carrier (intended parents' embryo, no genetic link), traditional surrogacy (rare, carrier's oocyte), donor gametes, legal contract requirements, and psychological counseling for all parties.</image>

Summary

• Infertility is defined as failure to conceive after 12 months of regular intercourse, with earlier evaluation recommended for women over 35 years of age
• The initial evaluation includes ovulation assessment, tubal evaluation via hysterosalpingogram, and semen analysis, conducted simultaneously for both partners
• Ovarian reserve testing with FSH, AMH, and antral follicle count predicts stimulation response but does not represent absolute fertility
• Male factor is present in 35 percent of infertile couples, with varicocele as the most common correctable cause and semen analysis as the first-line test
• Letrozole is the first-line ovulation induction agent for PCOS based on superior live birth rates compared to clomiphene citrate
• Intrauterine insemination involves placement of washed sperm in the uterus with 10 to 20 percent per-cycle success, recommended for 3 to 4 cycles before IVF
• In vitro fertilization involves stimulation, retrieval, fertilization, and transfer with 30 to 50 percent success rates that decline significantly with female age
• Intracytoplasmic sperm injection enables fertilization with a single sperm and is indicated for severe male factor infertility
• Ovarian hyperstimulation syndrome is the most serious ART complication, prevented by GnRH agonist trigger and freeze-all strategies
• Female age is the single most important factor affecting both natural fertility and assisted reproductive technology outcomes

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown